Partner Cliff Risman is quoted in an article for National Real Estate Investor, “Hotels Might Be a Good Bet for HNW Investors, But Which Types Should They Focus On? ” about which segments of the hotel sector hold the most potential for strong risk-adjusted yields.
Risman said high-net-worth investors should proceed with caution when investing in the hotel field. Unlike an office building or a warehouse, a hotel is a business with employees, inventory and other concerns, he noted.
“High-net-worth investors who jump into a hotel deal because they think it’s sexy, or because they like having dinner there, many times go away licking their wounds,” he said. “It’s a complicated business.”
Risman said high-net-worth investors should proceed with caution when investing in the hotel field. Unlike an office building or a warehouse, a hotel is a business with employees, inventory and other concerns, he noted.
“High-net-worth investors who jump into a hotel deal because they think it’s sexy, or because they like having dinner there, many times go away licking their wounds,” he said. “It’s a complicated business.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”